Evaluating a novel pharmacist‐led buprenorphine outreach service for treatment of opioid use disorder in individuals residing in supportive housing
- 14 January 2024
- journal article
- research article
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 7 (2) , 115-122
Abstract
Introduction: In San Francisco, there were 638 accidental overdose deaths involving opioids in 2022 alone, with opioid overdoses occurring at a disproportionate rate in the Black population and in those with fixed housing. Past studies attempting to address such disparities suggest that low‐barrier buprenorphine (BUP) treatment models may improve patient engagement and retention in care for marginalized populations. While such models have been studied among persons experiencing houselessness (PEH), less is known about the effects of such treatment models among individuals residing in permanent supportive housing (PSH). Objectives: To evaluate the impact of an innovative pharmacist‐led pilot service in providing more equitable and accessible BUP treatment to individuals residing in PSH. Methods: This was a 3‐month pre‐and‐post interventional pilot study to evaluate the impact of a novel pharmacist‐led outreach service on patient engagement in treatment with BUP for Opioid Use Disorder (OUD). The primary endpoint was treatment adherence, defined as 80% prescription days covered (PDC) in a 3‐month period. Secondary endpoints included change in PDC, linkage to office‐based care, incidence of overdose, emergency department (ED) presentations, and hospital admissions, as well as successful BUP initiation. Results: Thirty‐eight patients were enrolled in the pharmacist‐led BUP outreach service. Among the 38 patients, the mean age was 46 years and 16 (42%) were Black. Engagement with the service was associated with increased treatment adherence, with 14 patients (37%) achieving ≥80% PDC post‐intervention compared to 1 patient (3%) pre‐intervention ( p = 0.0009). Conclusion: A pharmacist‐led BUP outreach service was found to increase treatment adherence in individuals residing in PSH over 3 months. Low‐barrier BUP treatment models, such as that evaluated in this study, may help provide more equitable and accessible care that is critical in addressing the socioeconomic and racial disparities in opioid overdose deaths.Keywords
This publication has 18 references indexed in Scilit:
- Triple Threat: Response to the Crises of COVID-19, Homelessness, and Opioid Use Disorder With a Novel Approach to Buprenorphine Delivery: A Case SeriesJournal of Addiction Medicine, 2022
- Low-threshold Buprenorphine Treatment in a Syringe Services Program: Program Description and OutcomesJournal of Addiction Medicine, 2021
- Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid ReviewJournal of General Internal Medicine, 2020
- Impact of pharmacists on outcomes for patients with psychiatric or neurologic disordersMental Health Clinician, 2020
- Adherence to buprenorphine: An analysis of prescription drug monitoring program dataDrug and Alcohol Dependence, 2020
- A Scoping Review of Barriers and Facilitators to Implementation of Medications for Treatment of Opioid Use Disorder within the Criminal Justice SystemInternational Journal of Drug Policy, 2020
- A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success?The American Journal on Addictions, 2020
- Defining Low-threshold Buprenorphine TreatmentJournal of Addiction Medicine, 2020
- Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San FranciscoAddiction Science & Clinical Practice, 2019
- Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorderSubstance Abuse and Rehabilitation, 2018